TD Cowen raised the firm’s price target on CVS Health (CVS) to $100 from $99 and keeps a Buy rating on the shares. The firm update its estimates following 3Q25 results, where management raised its 2025 adj. EPS guide to $6.55-$6.65 from $6.30-$6.40 and provided preliminary a preliminary 2026 framework
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- CVS Health price target raised to $100 from $89 at BofA
- CVS Health price target raised to $93 from $81 at RBC Capital
- CVS Health Stock Feels the Heat as $5.7B Write-Down Weighs on ‘Record’ Q3
- CVS Health’s Strategic Growth and Financial Resilience Underpin Buy Rating